<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20240229050943&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20240229050943&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 29 Feb 2024 10:09:44 +0000</lastbuilddate>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Rethinking eGFR Comparisons in SGLT2 Inhibitor Research</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418013/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):e89. doi: 10.1016/j.jacc.2023.12.030.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418013/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418013</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.030>10.1016/j.jacc.2023.12.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418013</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Safia Chatur</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Rethinking eGFR Comparisons in SGLT2 Inhibitor Research</dc:title>
<dc:identifier>pmid:38418013</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.030</dc:identifier>
</item>
<item>
<title>Rethinking eGFR Comparisons in SGLT2 Inhibitor Research</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418012/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):e87. doi: 10.1016/j.jacc.2023.09.838.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418012/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418012</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.838>10.1016/j.jacc.2023.09.838</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418012</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Yuzuru Ohshiro</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Rethinking eGFR Comparisons in SGLT2 Inhibitor Research</dc:title>
<dc:identifier>pmid:38418012</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.838</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):959. doi: 10.1016/j.jacc.2024.01.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418011</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.020>10.1016/j.jacc.2024.01.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418011</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:38418011</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.020</dc:identifier>
</item>
<item>
<title>Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418010/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):956-958. doi: 10.1016/j.jacc.2023.12.029.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418010/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418010</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.029>10.1016/j.jacc.2023.12.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418010</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Malene K Hansen</dc:creator>
<dc:creator>Kevin K W Olesen</dc:creator>
<dc:creator>Christine Gyldenkerne</dc:creator>
<dc:creator>Pernille G Thrane</dc:creator>
<dc:creator>Nina Stødkilde-Jørgensen</dc:creator>
<dc:creator>Martin B Mortensen</dc:creator>
<dc:creator>Michael Maeng</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction</dc:title>
<dc:identifier>pmid:38418010</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.029</dc:identifier>
</item>
<item>
<title>The Legends Colloquium: A Conversation Between Eugene Braunwald and Valentin Fuster</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418009/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):951-955. doi: 10.1016/j.jacc.2024.01.019.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418009/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418009</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.019>10.1016/j.jacc.2024.01.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418009</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Martin E Goldman</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Legends Colloquium: A Conversation Between Eugene Braunwald and Valentin Fuster</dc:title>
<dc:identifier>pmid:38418009</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.019</dc:identifier>
</item>
<item>
<title>Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418008/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>Atrial fibrillation (AF) and heart failure (HF) are common cardiovascular conditions that frequently coexist. Among patients with HF, more than one-half also have AF. Both are associated with significant morbidity and mortality. Moreover, the prevalence of each is increasing globally, and this trend is expected to continue owing to an aging population and increased life expectancy. Diagnosis of AF in a patient with HF is associated with greater symptom burden, more frequent hospitalizations, and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):932-950. doi: 10.1016/j.jacc.2023.12.033.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation (AF) and heart failure (HF) are common cardiovascular conditions that frequently coexist. Among patients with HF, more than one-half also have AF. Both are associated with significant morbidity and mortality. Moreover, the prevalence of each is increasing globally, and this trend is expected to continue owing to an aging population and increased life expectancy. Diagnosis of AF in a patient with HF is associated with greater symptom burden, more frequent hospitalizations, and a worse prognosis. Guideline-directed medical therapy (GDMT) for HF can affect the incidence of AF. Once present, AF can influence the efficacy of some components of GDMT for HF. In this review, we discuss the effect of GDMT for HF across the spectrum of ejection fraction on prevention of AF as well as the benefit of GDMT in patients with vs without AF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418008/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418008</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.033>10.1016/j.jacc.2023.12.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418008</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Joshua D Newman</dc:creator>
<dc:creator>Eileen O'Meara</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Gianluigi Savarese</dc:creator>
<dc:creator>Patricia R Kelly</dc:creator>
<dc:creator>Orly Vardeny</dc:creator>
<dc:creator>Larry A Allen</dc:creator>
<dc:creator>Patrizio Lancellotti</dc:creator>
<dc:creator>Stephen S Gottlieb</dc:creator>
<dc:creator>Zainab Samad</dc:creator>
<dc:creator>Alanna A Morris</dc:creator>
<dc:creator>Nihar R Desai</dc:creator>
<dc:creator>Giuseppe M C Rosano</dc:creator>
<dc:creator>John R Teerlink</dc:creator>
<dc:creator>Clara Saldarriaga Giraldo</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38418008</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.033</dc:identifier>
</item>
<item>
<title>Anemia and Sex Disparity in CABG Mortality: In Search of a Grand Unified Theory</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):929-931. doi: 10.1016/j.jacc.2024.01.005.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418007</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.005>10.1016/j.jacc.2024.01.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418007</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Thomas A Schwann</dc:creator>
<dc:creator>Daniel T Engelman</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Anemia and Sex Disparity in CABG Mortality: In Search of a Grand Unified Theory</dc:title>
<dc:identifier>pmid:38418007</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.005</dc:identifier>
</item>
<item>
<title>Intraoperative Anemia Mediates Sex Disparity in Operative Mortality After Coronary Artery Bypass Grafting</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The association of female sex with increased CABG operative mortality is mediated to a large extent by intraoperative anemia. Avoiding nadir intraoperative hematocrit values below 22.0% may reduce sex differences in CABG operative mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):918-928. doi: 10.1016/j.jacc.2023.12.032.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Women undergoing coronary artery bypass grafting (CABG) have higher operative mortality than men.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to evaluate the relationship between intraoperative anemia (nadir intraoperative hematocrit), CABG operative mortality, and sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a cohort study of 1,434,225 isolated primary CABG patients (344,357 women) from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (2011-2022). The primary outcome was operative mortality. The attributable risk (AR) (the risk-adjusted strength of the association of female sex with CABG outcomes) for the primary outcome was calculated. Causal mediation analysis derived the total effect of female sex on operative mortality risk and the proportion of that effect mediated by intraoperative anemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Women had lower median nadir intraoperative hematocrit (22.0% [Q1-Q3: 20.0%-25.0%] vs 27.0% [Q1-Q3: 24.0%-30.0%], standardized mean difference 97.0%) than men. Women had higher operative mortality than men (2.8% vs 1.7%; P &lt; 0.001; adjusted OR: 1.36; 95% CI: 1.30-1.41). The AR of female sex for operative mortality was 1.21 (95% CI: 1.17-1.24). After adjusting for nadir intraoperative hematocrit, AR was reduced by 43% (1.12; 95% CI: 1.09-1.16). Intraoperative anemia mediated 38.5% of the increased mortality risk associated with female sex (95% CI: 32.3%-44.7%). Spline regression showed a stronger association between operative mortality and nadir intraoperative hematocrit at hematocrit values &lt;22.0% (P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The association of female sex with increased CABG operative mortality is mediated to a large extent by intraoperative anemia. Avoiding nadir intraoperative hematocrit values below 22.0% may reduce sex differences in CABG operative mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418006</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.032>10.1016/j.jacc.2023.12.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418006</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Lamia Harik</dc:creator>
<dc:creator>Robert H Habib</dc:creator>
<dc:creator>Arnaldo Dimagli</dc:creator>
<dc:creator>Mohamed Rahouma</dc:creator>
<dc:creator>Roberto Perezgrovas-Olaria</dc:creator>
<dc:creator>Giovanni Jr Soletti</dc:creator>
<dc:creator>Talal Alzghari</dc:creator>
<dc:creator>Kevin R An</dc:creator>
<dc:creator>Lisa Q Rong</dc:creator>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:creator>C Noel Bairey-Merz</dc:creator>
<dc:creator>Bjorn Redfors</dc:creator>
<dc:creator>Leonard Girardi</dc:creator>
<dc:creator>Mario Gaudino</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Intraoperative Anemia Mediates Sex Disparity in Operative Mortality After Coronary Artery Bypass Grafting</dc:title>
<dc:identifier>pmid:38418006</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.032</dc:identifier>
</item>
<item>
<title>Targeting the Natriuretic Peptide System to Improve Outcomes: PARADISE Lost or Found</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418005/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):915-917. doi: 10.1016/j.jacc.2024.01.009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418005/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418005</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.009>10.1016/j.jacc.2024.01.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418005</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jacob A Udell</dc:creator>
<dc:creator>David W J Armstrong</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Targeting the Natriuretic Peptide System to Improve Outcomes: PARADISE Lost or Found</dc:title>
<dc:identifier>pmid:38418005</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.009</dc:identifier>
</item>
<item>
<title>Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418004/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Compared with ramipril, sacubitril/valsartan did not significantly decrease the risk for cardiovascular death and HF in patients with AMI complicated by left ventricular dysfunction, irrespective of the type of AMI. (Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI; NCT02924727).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):904-914. doi: 10.1016/j.jacc.2024.01.002.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients who sustain an acute myocardial infarction (AMI), including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), remain at high risk for heart failure (HF), coronary events, and death. Angiotensin-converting enzyme inhibitors have been shown to significantly decrease the risk for cardiovascular events in both STEMI and NSTEMI patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The objectives were to determine whether angiotensin-receptor blockade and neprilysin inhibition with sacubitril/valsartan, compared with ramipril, has impact on reducing cardiovascular events according to the type of AMI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The PARADISE-MI (Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction) trial enrolled patients with AMI complicated by left ventricular dysfunction and/or pulmonary congestion and at least 1 risk-enhancing factor. Patients were randomized to either sacubitril/valsartan or ramipril. The primary endpoint was death from cardiovascular causes or incident HF. In this prespecified analysis, we stratified patients according to AMI type.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 5,661 enrolled patients, 4,291 (75.8%) had STEMI. These patients were younger and had fewer comorbidities and cardiovascular risk factors than NSTEMI patients. After adjustment for potential confounders, the risk for the primary outcome was marginally higher in NSTEMI vs STEMI patients (adjusted HR: 1.19; 95% CI: 1.00-1.41), with borderline statistical significance (P = 0.05). The primary composite outcome occurred at similar rates in patients randomized to sacubitril/valsartan vs ramipril in STEMI (10% vs 12%; HR: 0.87; 95% CI: 0.73-1.04; P = 0.13) and NSTEMI patients (17% vs 17%; HR: 0.97; 95% CI: 0.75-1.25; P = 0.80; P interaction = 0.53).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Compared with ramipril, sacubitril/valsartan did not significantly decrease the risk for cardiovascular death and HF in patients with AMI complicated by left ventricular dysfunction, irrespective of the type of AMI. (Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI; NCT02924727).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418004/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418004</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.002>10.1016/j.jacc.2024.01.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418004</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Douglas L Mann</dc:creator>
<dc:creator>Johny Nicolas</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Zi Michael Miao</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Prafulla Kerkar</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Aldo P Maggioni</dc:creator>
<dc:creator>Julio Núñez</dc:creator>
<dc:creator>Mpiko Ntsekhe</dc:creator>
<dc:creator>Jean-Lucien Rouleau</dc:creator>
<dc:creator>David Sim</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:creator>Marc A Pfeffer</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI</dc:title>
<dc:identifier>pmid:38418004</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.002</dc:identifier>
</item>
<item>
<title>Is There a Role for Routine Stress Testing After Multivessel or Left Main PCI?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418003/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):901-903. doi: 10.1016/j.jacc.2023.12.028.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418003/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418003</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.028>10.1016/j.jacc.2023.12.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418003</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Debabrata Mukherjee</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Is There a Role for Routine Stress Testing After Multivessel or Left Main PCI?</dc:title>
<dc:identifier>pmid:38418003</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.028</dc:identifier>
</item>
<item>
<title>Surveillance Stress Testing After Percutaneous Intervention for Patients With Multivessel or Left Main Coronary Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418002/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In high-risk patients with multivessel or left main CAD who underwent PCI, there was no incremental clinical benefit from routine surveillance functional-testing compared with standard care alone during follow-up. (Pragmatic Trial Comparing Symptom-Oriented Versus Routine Stress Testing in High-Risk Patients Undergoing Percutaneous Coronary Intervention [POST-PCI]; NCT03217877).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):890-900. doi: 10.1016/j.jacc.2023.12.027.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The optimal surveillance strategy after percutaneous coronary intervention (PCI) for high-risk patients with multivessel or left main coronary artery disease (CAD) remains uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to determine the prognostic role of routine functional testing in patients with multivessel or left main CAD who underwent PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The POST-PCI (Pragmatic Trial Comparing Symptom-Oriented Versus Routine Stress Testing in High-Risk Patients Undergoing Percutaneous Coronary Intervention) trial randomized high-risk PCI patients to routine functional testing at 1 year or standard care alone during follow-up. This analysis focused on participants with multivessel or left main CAD. The primary outcome was a composite of death from any cause, myocardial infarction, or hospitalization for unstable angina at 2 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1,706 initially randomized patients, 1,192 patients with multivessel (n = 833) or left main (n = 359) were identified, with 589 in the functional testing group and 603 in the standard care group. Two-year incidences of primary outcome were similar between the functional testing group and the standard care group (6.2% vs 5.7%, respectively; HR: 1.09; 95% CI: 0.68-1.74; P = 0.73). This trend persisted in both groups of multivessel (6.2% vs 5.7%; HR: 1.09; 95% CI: 0.62-1.89; P = 0.78) and left main disease (6.2% vs 5.7%; HR: 1.09; 95% CI: 0.46-2.56; P = 0.85) (P for interaction = 0.90). Routine surveillance functional testing was associated with increased rates of invasive angiography and repeat revascularization beyond 1 year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In high-risk patients with multivessel or left main CAD who underwent PCI, there was no incremental clinical benefit from routine surveillance functional-testing compared with standard care alone during follow-up. (Pragmatic Trial Comparing Symptom-Oriented Versus Routine Stress Testing in High-Risk Patients Undergoing Percutaneous Coronary Intervention [POST-PCI]; NCT03217877).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418002/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418002</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.027>10.1016/j.jacc.2023.12.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418002</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Joong Min Lee</dc:creator>
<dc:creator>Hoyun Kim</dc:creator>
<dc:creator>Young-Sun Park</dc:creator>
<dc:creator>Ha Hye Jo</dc:creator>
<dc:creator>So-Min Lim</dc:creator>
<dc:creator>Jinho Lee</dc:creator>
<dc:creator>Yeonwoo Choi</dc:creator>
<dc:creator>Do-Yoon Kang</dc:creator>
<dc:creator>Jung-Min Ahn</dc:creator>
<dc:creator>Seonok Kim</dc:creator>
<dc:creator>Yong-Hoon Yoon</dc:creator>
<dc:creator>Seung-Ho Hur</dc:creator>
<dc:creator>Cheol Hyun Lee</dc:creator>
<dc:creator>Won-Jang Kim</dc:creator>
<dc:creator>Se Hun Kang</dc:creator>
<dc:creator>Chul Soo Park</dc:creator>
<dc:creator>Bong-Ki Lee</dc:creator>
<dc:creator>Jung-Won Suh</dc:creator>
<dc:creator>Jae Woong Choi</dc:creator>
<dc:creator>Kee-Sik Kim</dc:creator>
<dc:creator>Su Nam Lee</dc:creator>
<dc:creator>Seung-Jung Park</dc:creator>
<dc:creator>Duk-Woo Park</dc:creator>
<dc:creator>POST-PCI Investigators</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Surveillance Stress Testing After Percutaneous Intervention for Patients With Multivessel or Left Main Coronary Disease</dc:title>
<dc:identifier>pmid:38418002</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.027</dc:identifier>
</item>
<item>
<title>Lipoprotein(a): Ready for Prime Time?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418001/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):887-889. doi: 10.1016/j.jacc.2024.01.004.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418001/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418001</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.004>10.1016/j.jacc.2024.01.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418001</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Nathan D Wong</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lipoprotein(a): Ready for Prime Time?</dc:title>
<dc:identifier>pmid:38418001</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.004</dc:identifier>
</item>
<item>
<title>Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418000/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In a large, contemporary U.S. cohort, elevated Lp(a) is independently associated with long-term MACE among individuals with and without baseline ASCVD. Our results suggest that the threshold for risk assessment may be different in primary vs secondary prevention cohorts.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):873-886. doi: 10.1016/j.jacc.2023.12.031.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lipoprotein(a) [Lp(a)] is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). However, whether the optimal Lp(a) threshold for risk assessment should differ based on baseline ASCVD status is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to assess the association between Lp(a) and major adverse cardiovascular events (MACE) among patients with and without baseline ASCVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We studied a retrospective cohort of patients with Lp(a) measured at 2 medical centers in Boston, Massachusetts, from 2000 to 2019. To assess the association of Lp(a) with incident MACE (nonfatal myocardial infarction [MI], nonfatal stroke, coronary revascularization, or cardiovascular mortality), Lp(a) percentile groups were generated with the reference group set at the first to 50th Lp(a) percentiles. Cox proportional hazards modeling was used to assess the association of Lp(a) percentile group with MACE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 16,419 individuals were analyzed with a median follow-up of 11.9 years. Among the 10,181 (62%) patients with baseline ASCVD, individuals in the 71st to 90th percentile group had a 21% increased hazard of MACE (adjusted HR: 1.21; P &lt; 0.001), which was similar to that of individuals in the 91st to 100th group (adjusted HR: 1.26; P &lt; 0.001). Among the 6,238 individuals without established ASCVD, there was a continuously higher hazard of MACE with increasing Lp(a), and individuals in the 91st to 100th Lp(a) percentile group had the highest relative risk with an adjusted HR of 1.93 (P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a large, contemporary U.S. cohort, elevated Lp(a) is independently associated with long-term MACE among individuals with and without baseline ASCVD. Our results suggest that the threshold for risk assessment may be different in primary vs secondary prevention cohorts.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418000/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418000</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.031>10.1016/j.jacc.2023.12.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418000</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Adam N Berman</dc:creator>
<dc:creator>David W Biery</dc:creator>
<dc:creator>Stephanie A Besser</dc:creator>
<dc:creator>Avinainder Singh</dc:creator>
<dc:creator>Arthur Shiyovich</dc:creator>
<dc:creator>Brittany N Weber</dc:creator>
<dc:creator>Daniel M Huck</dc:creator>
<dc:creator>Sanjay Divakaran</dc:creator>
<dc:creator>Jon Hainer</dc:creator>
<dc:creator>Gurleen Kaur</dc:creator>
<dc:creator>Michael J Blaha</dc:creator>
<dc:creator>Christopher P Cannon</dc:creator>
<dc:creator>Jorge Plutzky</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>John N Booth</dc:creator>
<dc:creator>J Antonio G López</dc:creator>
<dc:creator>Shia T Kent</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>Marcelo F Di Carli</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Ron Blankstein</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease</dc:title>
<dc:identifier>pmid:38418000</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.031</dc:identifier>
</item>
<item>
<title>Londa Schiebinger</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38417438/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>Dr. Londa Schiebinger is an international leader on the intersection of sex, gender, and science. In this interview with Cell, she discusses the Gendered Innovations project, the persistent STEM gender gap, the importance of considering sex- and gender-related variables and intersectionality in research, and the future of sex and gender research.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 21:S0092-8674(24)00114-4. doi: 10.1016/j.cell.2024.01.045. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Dr. Londa Schiebinger is an international leader on the intersection of sex, gender, and science. In this interview with Cell, she discusses the Gendered Innovations project, the persistent STEM gender gap, the importance of considering sex- and gender-related variables and intersectionality in research, and the future of sex and gender research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38417438/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38417438</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.045>10.1016/j.cell.2024.01.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38417438</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Londa Schiebinger</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Londa Schiebinger</dc:title>
<dc:identifier>pmid:38417438</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.045</dc:identifier>
</item>
<item>
<title>Novel drug therapies for atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418746/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Feb 28. doi: 10.1038/s41569-024-01004-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418746/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38418746</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01004-2>10.1038/s41569-024-01004-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418746</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Felix Wiedmann</dc:creator>
<dc:creator>Constanze Schmidt</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Novel drug therapies for atrial fibrillation</dc:title>
<dc:identifier>pmid:38418746</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01004-2</dc:identifier>
</item>
<item>
<title>Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38416633/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Drugs targeting the three traditional treatment pathways significantly improve outcomes in PAH, with significant treatment heterogeneity in patients with some comorbidities. Randomized clinical trials are warranted to identify the most effective treatment strategies in a personalized approach.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 28:ehae049. doi: 10.1093/eurheartj/ehae049. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Effective therapies that target three main signalling pathways are approved to treat pulmonary arterial hypertension (PAH). However, there are few large patient-level studies that compare the effectiveness of these pathways. The aim of this analysis was to compare the effectiveness of the treatment pathways in PAH and to assess treatment heterogeneity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A network meta-analysis was performed using individual participant data of 6811 PAH patients from 20 Phase III randomized clinical trials of therapy for PAH that were submitted to the US Food and Drug Administration. Individual drugs were grouped by the following treatment pathways: endothelin, nitric oxide, and prostacyclin pathways.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The mean (±standard deviation) age of the sample was 49.2 (±15.4) years; 78.4% were female, 59.7% had idiopathic PAH, and 36.5% were on background PAH therapy. After covariate adjustment, targeting the endothelin + nitric oxide pathway {β: 43.7 m [95% confidence interval (CI): 32.9, 54.4]}, nitric oxide pathway [β: 29.4 m (95% CI: 22.6, 36.3)], endothelin pathway [β: 25.3 m (95% CI: 19.8, 30.8)], and prostacyclin pathway [oral/inhaled β: 19.1 m (95% CI: 14.2, 24.0), intravenous/subcutaneous β: 24.4 m (95% CI: 15.1, 33.7)] significantly increased 6 min walk distance at 12 or 16 weeks compared with placebo. Treatments also significantly reduced the likelihood of having clinical worsening events. There was significant heterogeneity of treatment effects by age, body mass index, hypertension, diabetes, and coronary artery disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Drugs targeting the three traditional treatment pathways significantly improve outcomes in PAH, with significant treatment heterogeneity in patients with some comorbidities. Randomized clinical trials are warranted to identify the most effective treatment strategies in a personalized approach.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38416633/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38416633</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae049>10.1093/eurheartj/ehae049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38416633</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jude Moutchia</dc:creator>
<dc:creator>Robyn L McClelland</dc:creator>
<dc:creator>Nadine Al-Naamani</dc:creator>
<dc:creator>Dina H Appleby</dc:creator>
<dc:creator>John H Holmes</dc:creator>
<dc:creator>Jasleen Minhas</dc:creator>
<dc:creator>Jeremy A Mazurek</dc:creator>
<dc:creator>Harold I Palevsky</dc:creator>
<dc:creator>Corey E Ventetuolo</dc:creator>
<dc:creator>Steven M Kawut</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis</dc:title>
<dc:identifier>pmid:38416633</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae049</dc:identifier>
</item>
<item>
<title>Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38416593/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 28:ehae028. doi: 10.1093/eurheartj/ehae028. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38416593/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38416593</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae028>10.1093/eurheartj/ehae028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38416593</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Linda G Mellbin</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Jens-Peter David</dc:creator>
<dc:creator>Kathrine Ekström</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Søren Rasmussen</dc:creator>
<dc:creator>Tina Vilsbøll</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials</dc:title>
<dc:identifier>pmid:38416593</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae028</dc:identifier>
</item>
<item>
<title>Age and Computed Tomography and Invasive Coronary Angiography in Stable Chest Pain: A Prespecified Secondary Analysis of the DISCHARGE Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38416472/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Age did not modify the effect of randomization group on the primary outcome of MACE but did modify the effect on major procedure-related complications. Results suggest that CT was associated with a lower risk of major procedure-related complications in younger patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 28. doi: 10.1001/jamacardio.2024.0001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The effectiveness and safety of computed tomography (CT) and invasive coronary angiography (ICA) in different age groups is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the association of age with outcomes of CT and ICA in patients with stable chest pain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The assessor-blinded Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease (DISCHARGE) randomized clinical trial was conducted between October 2015 and April 2019 in 26 European centers. Patients referred for ICA with stable chest pain and an intermediate probability of obstructive coronary artery disease were analyzed in an intention-to-treat analysis. Data were analyzed from July 2022 to January 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomly assigned to a CT-first strategy or a direct-to-ICA strategy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: MACE (ie, cardiovascular death, nonfatal myocardial infarction, or stroke) and major procedure-related complications. The primary prespecified outcome of this secondary analysis of age was major adverse cardiovascular events (MACE) at a median follow-up of 3.5 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 3561 patients (mean [SD] age, 60.1 [10.1] years; 2002 female [56.2%]), 2360 (66.3%) were younger than 65 years, 982 (27.6%) were between ages 65 to 75 years, and 219 (6.1%) were older than 75 years. The primary outcome was MACE at a median (IQR) follow-up of 3.5 (2.9-4.2) years for 3523 patients (99%). Modeling age as a continuous variable, age, and randomization group were not associated with MACE (hazard ratio, 1.02; 95% CI, 0.98-1.07; P for interaction = .31). Age and randomization group were associated with major procedure-related complications (odds ratio, 1.15; 95% CI, 1.05-1.27; P for interaction = .005), which were lower in younger patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Age did not modify the effect of randomization group on the primary outcome of MACE but did modify the effect on major procedure-related complications. Results suggest that CT was associated with a lower risk of major procedure-related complications in younger patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02400229.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38416472/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38416472</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0001>10.1001/jamacardio.2024.0001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38416472</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>DISCHARGE Trial Group</dc:creator>
<dc:creator>Maria Bosserdt</dc:creator>
<dc:creator>Lina M Serna-Higuita</dc:creator>
<dc:creator>Gudrun Feuchtner</dc:creator>
<dc:creator>Bela Merkely</dc:creator>
<dc:creator>Klaus F Kofoed</dc:creator>
<dc:creator>Theodora Benedek</dc:creator>
<dc:creator>Patrick Donnelly</dc:creator>
<dc:creator>José Rodriguez-Palomares</dc:creator>
<dc:creator>Andrejs Erglis</dc:creator>
<dc:creator>Cyril Štechovský</dc:creator>
<dc:creator>Gintare Šakalyte</dc:creator>
<dc:creator>Nada Cemerlic Adic</dc:creator>
<dc:creator>Matthias Gutberlet</dc:creator>
<dc:creator>Jonathan D Dodd</dc:creator>
<dc:creator>Ignacio Diez</dc:creator>
<dc:creator>Gershan Davis</dc:creator>
<dc:creator>Elke Zimmermann</dc:creator>
<dc:creator>Cezary Kepka</dc:creator>
<dc:creator>Radosav Vidakovic</dc:creator>
<dc:creator>Marco Francone</dc:creator>
<dc:creator>Malgorzata Ilnicka-Suckiel</dc:creator>
<dc:creator>Fabian Plank</dc:creator>
<dc:creator>Juhani Knuuti</dc:creator>
<dc:creator>Rita Faria</dc:creator>
<dc:creator>Stephen Schröder</dc:creator>
<dc:creator>Colin Berry</dc:creator>
<dc:creator>Luca Saba</dc:creator>
<dc:creator>Balazs Ruzsics</dc:creator>
<dc:creator>Nina Rieckmann</dc:creator>
<dc:creator>Christine Kubiak</dc:creator>
<dc:creator>Kristian Schultz Hansen</dc:creator>
<dc:creator>Jacqueline Müller-Nordhorn</dc:creator>
<dc:creator>Bálint Szilveszter</dc:creator>
<dc:creator>Per E Sigvardsen</dc:creator>
<dc:creator>Imre Benedek</dc:creator>
<dc:creator>Clare Orr</dc:creator>
<dc:creator>Filipa Xavier Valente</dc:creator>
<dc:creator>Ligita Zvaigzne</dc:creator>
<dc:creator>Vojtech Suchánek</dc:creator>
<dc:creator>Antanas Jankauskas</dc:creator>
<dc:creator>Filip Adic</dc:creator>
<dc:creator>Michael Woinke</dc:creator>
<dc:creator>Mark Hensey</dc:creator>
<dc:creator>Iñigo Lecumberri</dc:creator>
<dc:creator>Erica Thwaite</dc:creator>
<dc:creator>Michael Laule</dc:creator>
<dc:creator>Mariusz Kruk</dc:creator>
<dc:creator>Aleksandar N Neskovic</dc:creator>
<dc:creator>Massimo Mancone</dc:creator>
<dc:creator>Donata Kusmierz</dc:creator>
<dc:creator>Mikko Pietilä</dc:creator>
<dc:creator>Vasco Gama Ribeiro</dc:creator>
<dc:creator>Tanja Drosch</dc:creator>
<dc:creator>Christian Delles</dc:creator>
<dc:creator>Maurizio Porcu</dc:creator>
<dc:creator>Michael Fisher</dc:creator>
<dc:creator>Melinda Boussoussou</dc:creator>
<dc:creator>Charlotte Kragelund</dc:creator>
<dc:creator>Rosca Aurelian</dc:creator>
<dc:creator>Stephanie Kelly</dc:creator>
<dc:creator>Bruno Garcia Del Blanco</dc:creator>
<dc:creator>Ainhoa Rubio</dc:creator>
<dc:creator>Pál Maurovich-Horvat</dc:creator>
<dc:creator>Jens D Hove</dc:creator>
<dc:creator>Ioana Rodean</dc:creator>
<dc:creator>Susan Regan</dc:creator>
<dc:creator>Hug Cuellar-Calabria</dc:creator>
<dc:creator>Levente Molnár</dc:creator>
<dc:creator>Linnea Larsen</dc:creator>
<dc:creator>Roxana Hodas</dc:creator>
<dc:creator>Adriane E Napp</dc:creator>
<dc:creator>Robert Haase</dc:creator>
<dc:creator>Sarah Feger</dc:creator>
<dc:creator>Mahmoud Mohamed</dc:creator>
<dc:creator>Konrad Neumann</dc:creator>
<dc:creator>Henryk Dreger</dc:creator>
<dc:creator>Matthias Rief</dc:creator>
<dc:creator>Viktoria Wieske</dc:creator>
<dc:creator>Melanie Estrella</dc:creator>
<dc:creator>Peter Martus</dc:creator>
<dc:creator>Harold C Sox</dc:creator>
<dc:creator>Marc Dewey</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Age and Computed Tomography and Invasive Coronary Angiography in Stable Chest Pain: A Prespecified Secondary Analysis of the DISCHARGE Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38416472</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0001</dc:identifier>
</item>
<item>
<title>Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38416462/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study developed and validated 1 of the first aortic stenosis PRSs. While aortic stenosis genetic risk was independent from clinical risk factors and performed comparably to all other risk factors besides age, genetic risk resulted in only a small improvement in overall aortic stenosis risk discrimination beyond age and clinical risk factors. This work sets the stage for further development of an aortic stenosis PRS.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 28. doi: 10.1001/jamacardio.2024.0011. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Polygenic risk scores (PRSs) have proven to be as strong as or stronger than established clinical risk factors for many cardiovascular phenotypes. Whether this is true for aortic stenosis remains unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To develop a novel aortic stenosis PRS and compare its aortic stenosis risk estimation to established clinical risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a longitudinal cohort study using data from the Million Veteran Program (MVP; 2011-2020), UK Biobank (2006-2010), and 6 Thrombolysis in Myocardial Infarction (TIMI) trials, including DECLARE-TIMI 58 (2013-2018), FOURIER (TIMI 59; 2013-2017), PEGASUS-TIMI 54 (2010-2014), SAVOR-TIMI 53 (2010-2013), SOLID-TIMI 52 (2009-2014), and ENGAGE AF-TIMI 58 (2008-2013), which were a mix of population-based and randomized clinical trials. Individuals from UK Biobank and the MVP meeting a previously validated case/control definition for aortic stenosis were included. All individuals from TIMI trials were included unless they had a documented preexisting aortic valve replacement. Analysis took place from January 2022 to December 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: PRS for aortic stenosis (developed using data from MVP and validated in UK Biobank) and other previously validated cardiovascular PRSs, defined either as a continuous variable or as low (bottom 20%), intermediate, and high (top 20%), and clinical risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES: Aortic stenosis (defined using International Classification of Diseases or Current Procedural Terminology codes in UK Biobank and MVP or safety event data in the TIMI trials).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The median (IQR) age in MVP was 67 (57-73) years, and 135 140 of 147 104 participants (92%) were male. The median (IQR) age in the TIMI trials was 66 (54-78) years, and 45 524 of 59 866 participants (71%) were male. The best aortic stenosis PRS incorporated 5 170 041 single-nucleotide variants and was associated with aortic stenosis in both the MVP testing sample (odds ratio, 1.41; 95% CI, 1.37-1.45 per 1 SD PRS; P = 4.6 × 10-116) and TIMI trials (hazard ratio, 1.44; 95% CI, 1.27-1.62 per 1 SD PRS; P = 3.2 × 10-9). Among genetic and clinical risk factors, the aortic stenosis PRS performed comparably to most risk factors besides age, and within a given age range, the combination of clinical and genetic risk factors was additive, providing a 3- to 4-fold increased gradient of risk of aortic stenosis. However, the addition of the aortic stenosis PRS to a model including clinical risk factors only improved risk discrimination of aortic stenosis by 0.01 to 0.02 (C index in MVP: 0.78 with clinical risk factors, 0.79 with risk factors and aortic stenosis PRS; C index in TIMI: 0.71 with clinical risk factors, 0.73 with risk factors and aortic stenosis PRS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study developed and validated 1 of the first aortic stenosis PRSs. While aortic stenosis genetic risk was independent from clinical risk factors and performed comparably to all other risk factors besides age, genetic risk resulted in only a small improvement in overall aortic stenosis risk discrimination beyond age and clinical risk factors. This work sets the stage for further development of an aortic stenosis PRS.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38416462/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38416462</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0011>10.1001/jamacardio.2024.0011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38416462</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Aeron M Small</dc:creator>
<dc:creator>Giorgio E M Melloni</dc:creator>
<dc:creator>Frederick K Kamanu</dc:creator>
<dc:creator>Brian A Bergmark</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:creator>Robert P Giugliano</dc:creator>
<dc:creator>Benjamin M Scirica</dc:creator>
<dc:creator>Deepak Bhatt</dc:creator>
<dc:creator>Elliott M Antman</dc:creator>
<dc:creator>Itamar Raz</dc:creator>
<dc:creator>Stephen D Wiviott</dc:creator>
<dc:creator>Buu Truong</dc:creator>
<dc:creator>Peter W F Wilson</dc:creator>
<dc:creator>Kelly Cho</dc:creator>
<dc:creator>Christopher J O'Donnell</dc:creator>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:creator>Steve A Lubitz</dc:creator>
<dc:creator>Patrick Ellinor</dc:creator>
<dc:creator>Gina M Peloso</dc:creator>
<dc:creator>Christian T Ruff</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Nicholas A Marston</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis</dc:title>
<dc:identifier>pmid:38416462</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0011</dc:identifier>
</item>
<item>
<title>Change to Open Access Status</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38416454/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240229050943&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 28. doi: 10.1001/jamacardio.2024.0582. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38416454/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240229050943&v=2.18.0.post9+e462414">38416454</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0582>10.1001/jamacardio.2024.0582</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38416454</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Change to Open Access Status</dc:title>
<dc:identifier>pmid:38416454</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0582</dc:identifier>
</item>





























</channel>
</rss>